FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR

Euglycemic diabetic ketoacidosis (euDKA) is a rare but life-threatening complication in users of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor prescribed for type 2 diabetes mellitus (T2DM), where normal or mildly elevated blood glucose levels (<200–250 mg/dL) frequently delay clinical recognition. This narrative literature review aimed to identify the clinical patterns and reporting frequency of precipitating factors accompanying diabetic ketoacidosis (DKA and euDKA) in patients treated with empagliflozin, rather than estimating epidemiological risk. A structured search was conducted on PubMed for English-language case reports with full text available published between January 1, 2016, and September 15, 2026, using the query (empagliflozin OR "SGLT2 inhibitor") AND ("diabetic ketoacidosis" OR "euglycemic diabetic ketoacidosis"). Study selection followed the PRISMA 2020 flow diagram and the PEO (Population, Exposure, Outcome) framework, conducted independently by two reviewers with consensus resolution by a third reviewer, yielding 18 eligible case reports. Methodological quality was appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports (15 high quality, 3 moderate quality). Through hybrid thematic coding, precipitating factors were organized hierarchically into three mechanistic domains comprising seven categories, and the proportion of included case reports reporting each factor (reporting frequency) was calculated; a single case report could involve multiple overlapping triggers. The highest reporting frequencies were observed for carbohydrate restriction and inadequate nutritional intake (13/18 reports; 72.2%), perioperative periods, medical procedures, and fasting (8/18; 44.4%), and acute infections (7/18; 38.9%), followed by the initial phase of therapy ≤2 months (6/18; 33.3%), insulin deficiency (5/18; 27.8%), endocrine comorbidities and malignancies (4/18; 22.2%), and non-infectious acute events (4/18; 22.2%). In conclusion, DKA/euDKA in empagliflozin users is multifactorial, driven by the interplay between drug-induced glucosuria and acute carbohydrate depletion, catabolic stress, or insulinopenia. Because case reports lack a population denominator and are subject to publication bias, these reporting frequencies reflect clinical trigger patterns rather than comparative clinical risk.

Authors

Institutions

Publication Details

Journal
Journal of Health and Nursing.
Published
2026-11-19
DOI
https://doi.org/10.58738/jhn.v4i2.2011
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR

Mally Ghinan Sholih, Anisa Amanda Putri, Mutiara Nurhalidza Sakinah
Journal of Health and Nursing.
Diabetes Treatment and Management
article

FAKTOR PENCETUS KETOASIDOSIS DIABETIK PADA PENGGUNA EMPAGLIFLOZIN: TINJAUAN LITERATUR

Mally Ghinan Sholih, Anisa Amanda Putri, Mutiara Nurhalidza Sakinah
article en

Abstract

Euglycemic diabetic ketoacidosis (euDKA) is a rare but life-threatening complication in users of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor prescribed for type 2 diabetes mellitus (T2DM), where normal or mildly elevated blood glucose levels (<200–250 mg/dL) frequently delay clinical recognition. This narrative literature review aimed to identify the clinical patterns and reporting frequency of precipitating factors accompanying diabetic ketoacidosis (DKA and euDKA) in patients treated with empagliflozin, rather than estimating epidemiological risk. A structured search was conducted on PubMed for English-language case reports with full text available published between January 1, 2016, and September 15, 2026, using the query (empagliflozin OR "SGLT2 inhibitor") AND ("diabetic ketoacidosis" OR "euglycemic diabetic ketoacidosis"). Study selection followed the PRISMA 2020 flow diagram and the PEO (Population, Exposure, Outcome) framework, conducted independently by two reviewers with consensus resolution by a third reviewer, yielding 18 eligible case reports. Methodological quality was appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports (15 high quality, 3 moderate quality). Through hybrid thematic coding, precipitating factors were organized hierarchically into three mechanistic domains comprising seven categories, and the proportion of included case reports reporting each factor (reporting frequency) was calculated; a single case report could involve multiple overlapping triggers. The highest reporting frequencies were observed for carbohydrate restriction and inadequate nutritional intake (13/18 reports; 72.2%), perioperative periods, medical procedures, and fasting (8/18; 44.4%), and acute infections (7/18; 38.9%), followed by the initial phase of therapy ≤2 months (6/18; 33.3%), insulin deficiency (5/18; 27.8%), endocrine comorbidities and malignancies (4/18; 22.2%), and non-infectious acute events (4/18; 22.2%). In conclusion, DKA/euDKA in empagliflozin users is multifactorial, driven by the interplay between drug-induced glucosuria and acute carbohydrate depletion, catabolic stress, or insulinopenia. Because case reports lack a population denominator and are subject to publication bias, these reporting frequencies reflect clinical trigger patterns rather than comparative clinical risk.

Journal of Health and Nursing.Vol. 4(2)
University of Singaperbangsa Karawang (ID)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon